Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.71
$0.531.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -91.28% | -60.75% | -54.76% | 50.73% | 259.03% |
| Total Depreciation and Amortization | 59.63% | 59.35% | 12.37% | -7.54% | -7.44% |
| Total Amortization of Deferred Charges | -23.20% | -27.46% | -43.13% | -29.06% | -22.17% |
| Total Other Non-Cash Items | 309.52% | -143.41% | -49.53% | 107.67% | -91.06% |
| Change in Net Operating Assets | -179.63% | 899.67% | -824.44% | -105.56% | 77.41% |
| Cash from Operations | -10.56% | 15.42% | -112.16% | -32.41% | 123.83% |
| Capital Expenditure | -40.49% | -247.56% | -275.38% | -382.14% | -222.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.42% | 55.11% | 600.90% | 79.27% | -- |
| Cash from Investing | 46.60% | 53.13% | -6,413.95% | 78.65% | -10,200.00% |
| Total Debt Issued | -- | 88.30% | -- | -- | -- |
| Total Debt Repaid | 64.77% | 64.77% | -259.18% | -72.48% | 71.99% |
| Issuance of Common Stock | -54.88% | -94.66% | 4.55% | 357.15% | 13.54% |
| Repurchase of Common Stock | 17.72% | -0.28% | 99.72% | -18,479.55% | -66.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -88.30% | -- | -- | -- |
| Cash from Financing | 53.39% | 39.14% | 256.19% | -152.47% | -179.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 298.14% | 261.37% | -331.99% | -536.34% | -110.79% |